Ketoconazole increases plasma concentrations of antimalarial mefloquine in healthy human volunteers

Journal of Clinical Pharmacy and Therapeutics

Volumn 30, Issue 3, 2005, Pages 285-290

  Ridtitid, Wibool ^a   Wongnawa, M ^a   Mahatthanatrakul, W ^a   Raungsri, N ^a   Sunbhanich, M ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

Drug drug interactions; Ketoconazole; Mefloquine; Pharmacokinetics; Plasma concentrations

Indexed keywords

ANTIMALARIAL AGENT; CARBOXYLIC ACID DERIVATIVE; CYTOCHROME P450 3A4; KETAZOL; KETOCONAZOLE; MEFLOQUINE; METHAQUALONE; ANTIFUNGAL AGENT; CYP3A PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; ULTRAVIOLET RADIATION; VOLUNTEER; BLOOD; DRUG ANTAGONISM; DRUG INTERACTION; HALF LIFE TIME;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; ANTIMALARIALS; AREA UNDER CURVE; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HALF-LIFE; HUMANS; KETOCONAZOLE; MALE; MEFLOQUINE;

EID: 23844442993     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2005.00651.x     Document Type: Article

References (25)

1. Palmer KJ, Holliday SM, Brogden RN (1993) Mefloquine: a review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs, 45, 430-475.
2. Simpson JA, Price R, ter Kuile F et al. (1999) Population pharmacokinetics of mefloquine in patients with acute falciparum malaria. Clinical Pharmacology and Therapeutics, 66, 472-484.
3. Karbwang J, White NJ (1990) Clinical pharmaco-kinetics of mefloquine. Clinical Pharmacokinetics, 19, 264-279.
4. Nosten F, Price RN (1995) New antimalarials a risk-benefit analysis. Drug Safety, 12, 264-273.
5. ter Kuile FO, Nosten F, Thieren M et al. (1992) High dose mefloquine in the treatment of multidrug resistant falciparum malaria. Journal of Infectious Diseases, 166, 1393-1400.
6. Mirghani RA, Hellgren U, Westerberg PA, Ericsson O, Bertilsson L, Gustafsson LL (1999) The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. Clinical Pharmacology and Therapeutics, 66, 454-460.
7. Venkatakrishnan K, Von Moltke LL, Greenblatt DJ (2000) Effects of the antifungal agents on oxidative drug metabolism. Clinical Pharmacokinetics, 38, 111-180.
8. Bergqvist Y, Hellgren U, Churchill FC (1988) High-performance liquid chromatography assay for the simultaneous monitoring of mefloquine and its metabolite in biological samples using protein precipitation and ion-pair extraction. Journal of Chromatography, 432, 253-263.
9. White NJ (1988) Drug treatment and prevention of malaria. European Journal of Clinical Pharmacology, 34, 1-14.
10. White NJ (1996) Malaria. In: Cook GC, ed. Manson's Tropical Disease. Philadelphia: WB Saunders, 1078-1164.
11. Zhao XJ, Yokoyama H, Chiba K, Wanwimolruk S, Ishizaki T (1996) Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human liver microsomes and nine recombinant human cytochromes P450. Journal of Pharmacology and Experimental Therapeutics, 279, 1327-1334.
12. Mirghani RA, Hellgren U, Bertilsson L, Gustafsson LL, Ericsson O (2003) Metabolism and elimination of quinine in healthy volunteers. European Journal of Clinical Pharmacology, 59, 423-427.
13. Ridtitid W, Wongnawa M, Mahatthanatrakul W, Phaipenkong P, Sunbhanich M (2001) Effect of ketoconazole and itraconanazole on plasma concentrations of quinine in normal healthy volunteers. Thai Journal of Pharmacology, 23, 101-108.
14. Venkatakrishnan K, Von Moltke LL, Greenblatt DJ (2000) Effects of the antifungal agents on oxidative drug metabolism. Clinical Pharmacokinetics, 38, 111-180.
15. Suzuki S, Kurata N, Nishimua Y, Yasuhara H, Satoh T (2000) Effects of imidazole antimycotics on the liver microsomal cytochrome P450 isoforms in rats: comparison of in vitro and ex vivo studies. European Journal of Drug Metabolism and Pharmacokinetics, 25, 121-126.
16. Tsunoda SM, Velez RL, Von Moltke LL, Greenblatt DJ (1999) Differentiation of intestinal and hepatic cytochrome P4503A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clinical Pharmacology and Therapeutics, 66, 461-471.
17. Sikka SC, Swerdloff RS, Rajfer J (1985) In vitro inhibition of testosterone biosynthesis by ketoconazole. Endocrinology, 116, 1920-1925.
18. Crevoisier C, Handschin J, Barre J, Roumenov D, Kleinbloesem C (1997) Food increases the bioavailability of mefloquine. European Journal of Clinical Pharmacology, 53, 135-139.
19. Ridtitid W, Wongnawa M, Mahatthanatrakul W, Chaipol P, Sunbhanich M (2000) Effect of rifampin on plasma concentrations of mefloquine in healthy volunteers. Journal of Pharmacy and Pharmacology, 52, 1265-1269.
20. Villikka K, Kivisto KT, Backman JT, Olkkola KT, Neuvonen PJ (1997) Triazolam is ineffective in patients taking rifampin. Clinical Pharmacology and Therapeutics, 61, 8-14.
21. Wildt SN, Kearns GL, Leeder JS, Anker JN (1999) Cytochrome P450 3A ontogeny and drug disposition. Clinical Pharmacokinetics, 37, 485-505.
22. Sunbhanich M, Ridtitid W, Wongnawa M, Aeksiripong S, Chamnongchob P (1997) Effect of cimetidine on an oral single-dose mefloquine pharmacokinetics in humans. Asia Pacific Journal of Pharmacology, 12, 51-55.
23. Lin JH (2003) Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Advanced Drug Delivery Reviews, 55, 53-81.
24. Choo EF, Leake B, Wandel C, Imamura H, Wood AJJ, Wilkinson GR, Kim RB (2000) Pharmacological inhibition of P- glycoprotein transports enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metabolism and Disposition, 28, 655-660.
25. Hesselink DA, van Schaik RHN, van der Heiden IP et al. (2003) Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clinical Pharmacology and Therapeutics, 74, 245-254.